Резултати

еНаука >  Резултати >  The consequences of the new European reclassification of non-invasive brain stimulation devices and the medical device regulations pose an existential threat to research and treatment: An invited opinion paper
Назив: The consequences of the new European reclassification of non-invasive brain stimulation devices and the medical device regulations pose an existential threat to research and treatment: An invited opinion paper
Аутори: Antal, Andrea; Ganho-Ávila, Ana; Assecondi, Sara; Barbour, Tracy; Bjekić, Jovana  ; Blumberger, Daniel M.; Bolognini, Nadia; Brunelin, Jerome; Chanes, Lorena; Dale, Matthew;
Година: 2024
Публикација: Clinical Neurophysiology
ISSN: 1388-2457 Clinical Neurophysiology Претражи идентификатор
Издавач: Elsevier
Тип резултата: Научни чланак
DOI: 10.1016/j.clinph.2024.03.039
WoS-ID: 001254826300001
Scopus-ID: 2-s2.0-85191581996
PMID: 38679530
URI: https://enauka.gov.rs/handle/123456789/918291
https://rimi.imi.bg.ac.rs/handle/123456789/1479
http://rimi.imi.bg.ac.rs/handle/123456789/1479
Пројекат: AA is supported by the DFG (AN 687/9-1, VIRON), EU-Horizon 2020 (PAINLESS, 101057367). AGA is supported by the Portuguese Foundation for Science and Technology (FCT) Grants 2020.02059.CEECIND (https://doi.org/10.54499/2020.02059.CEECIND/CP1609/CT0015). The Center for Research in Neuropsychology and Cognitive and Behavioral Intervention (CINEICC) of the Faculty of Psychology and Educational Sciences of the University of Coimbra is supported by the Portuguese Foundation for Science and Technology and the Portuguese Ministry of Education and Science through national funds and co financed by FEDER through COMPETE2020 under the PT2020 Partnership Agreement [UID/PSI/01662/2013]. BL got research funding from the Tinnitus Research Initiative, Bayhost, the German Research Foundation, the German Bundesministerium für Bildung und Forschung, the American Tinnitus Association, AstraZeneca, cerbomed, Neuromod and the European Union’s Horizon 2020 research and innovation programme, funding for equipment from MagVenture and Deymed Diagnostic; travel and accommodation payments from Eli Lilly, Lundbeck, Servier, and Pfizer; royalties from Springer and he owns shares of Sea Pharma. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Family Research Institute. He received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. He was the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He also received in kind equipment support from Magventure for two investigator initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. He is a scientific advisor for Sooma Medical. He is the Co-Chair of the Clinical Standards Committee of the Clinical TMS Society (unpaid). LC is supported by the Ministry of Science and Innovation of Spain (PID2020-119677RB-I00), the Government of Catalonia (2021SGR01010) and the Catalan Institution for Research and Advanced Studies (ICREA Acadèmia).
Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200015 (Univerzitet u Beogradu, Institut za medicinska istraživanja)
TWINNIBS - Twinning for excellence in non-invasive brain stimulation in Western Balkans
SU is supported by the University of Oulu and the Research Council of Finland Profi 7 352788.
М-категорија: 
21M21 - Водећи међународни часопис категорије M21

18
SCOPUSTM
6
PubMed CentralTM
12
WEB OF SCIENCETM
Алт метрика
Dimensions
Unpaywall

Резултати на еНаука су заштићени ауторским правима и сва права су задржана, осим ако није другачије назначено.